Although in vitro inhibition of HER3 has shown antitumor effects, prior clinical trials using ERBB-targeting agents (including HER2 and HER3 inhibitors) failed to demonstrate substantial clinical benefit in prostate cancer [23]. Here, ERBB2 is linked to prostate cancer.